Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 1,745 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biomarker blood draw Clear all
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab, Bevacizumab, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
San Francisco, California • St Louis, Missouri • Charlotte, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 1:33 AM EDT
Completed Phase 2 Interventional

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

NCT00003145
View directory record Official record
Conditions
Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease, Recurrent Disease
Interventions
Fludarabine Phosphate, Total-Body Irradiation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil, Therapeutic Allogeneic Lymphocytes, Laboratory Biomarker Analysis
Drug · Radiation · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 74 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 30, 2026, 1:33 AM EDT
Terminated Not applicable Interventional

Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant

NCT02240381
View directory record Official record
Conditions
Diabetes Mellitus, Malignant Neoplasm
Interventions
assessment of therapy complications, laboratory biomarker analysis
Procedure · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 30, 2026, 1:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

NCT00791037
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, leukapheresis, ex vivo-expanded HER2-specific T cells, cyclophosphamide, sargramostim, laboratory biomarker analysis
Biological · Procedure · Drug + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 30, 2026, 1:33 AM EDT
Completed No phase listed Observational

Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy

NCT00693329
View directory record Official record
Conditions
Cardiovascular Surgery With Coronary Angiography
Interventions
Not listed
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Petoskey, Michigan • Providence, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2009 · Synced Oct 30, 2026, 1:33 AM EDT
Completed Not applicable Interventional

Improving Sleep and AD Biomarkers

NCT06029894
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Citicoline Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Emory University
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 30, 2026, 1:33 AM EDT
Recruiting Phase 2 Interventional

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

NCT06330805
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Contrast Agent, Leuprolide, Magnetic Resonance Imaging, Physical Performance Testing, Relugolix
Procedure · Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 30, 2026, 1:33 AM EDT
Completed No phase listed Observational

Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer

NCT00898703
View directory record Official record
Conditions
Breast Cancer
Interventions
flow cytometry, immunoenzyme technique, laboratory biomarker analysis
Other
Lead sponsor
University of Arizona
Other
Eligibility
Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 30, 2026, 1:33 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

NCT01476839
View directory record Official record
Conditions
Recurrent Adult Hodgkin Lymphoma
Interventions
basiliximab, carmustine, etoposide, cytarabine, melphalan, pharmacological study, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, yttrium Y 90-labeled basiliximab
Biological · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 1:33 AM EDT
Recruiting Not applicable Interventional

T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas

NCT07447531
View directory record Official record
Conditions
Malignant Glioma
Interventions
T2 (Observed)-Weighted Imaging, Biospecimen Collection, Magnetic Resonance Imaging
Procedure
Lead sponsor
John M. Buatti
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 30, 2026, 1:33 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D)

NCT06908057
View directory record Official record
Conditions
Type 1 Diabetes, Celiac Disease
Interventions
Blood Draw
Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
2 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 1:33 AM EDT
Completed No phase listed Observational

Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes

NCT02238327
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, HIV, Emphysema
Interventions
blood draw, questionnaires, Lung function testing, Six-Minute walk test, Quantitative CT scans, Nasal secretion and cell collection, Echocardiogram
Procedure · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 30, 2026, 1:33 AM EDT
Terminated Not applicable Interventional Results available

Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer

NCT00773773
View directory record Official record
Conditions
Prostate Cancer, Elevated Prostate Specific Antigen (PSA)
Interventions
serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
4
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 30, 2026, 1:33 AM EDT
Completed Phase 3 Interventional

Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT00088894
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
gemcitabine hydrochloride, bevacizumab, placebo, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 30, 2026, 1:33 AM EDT
Completed Phase 1 Interventional

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

NCT03003546
View directory record Official record
Conditions
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Laboratory Biomarker Analysis, Nab-paclitaxel/Rituximab-coated Nanoparticle AR160, Pharmacological Study
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 30, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT03023046
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
Cyclophosphamide, Dasatinib, Doxorubicin, Etoposide, Imatinib Mesylate, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 30, 2026, 1:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions

NCT00436696
View directory record Official record
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
9,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
2
States / cities
Jackson, Mississippi • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 30, 2026, 1:33 AM EDT
Completed No phase listed Observational

Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer

NCT00766454
View directory record Official record
Conditions
Breast Cancer
Interventions
DNA analysis, mutation analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, evaluation of cancer risk factors
Genetic · Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years · Female only
Enrollment
1,104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 30, 2026, 1:33 AM EDT
Completed Phase 1 Interventional

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

NCT01434303
View directory record Official record
Conditions
HER2/Neu Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Entinostat, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 30, 2026, 1:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dehydration, Rehydration, and Blood Viscosity

NCT02118883
View directory record Official record
Conditions
Dehydration
Interventions
Essentia Water, Bottled water
Other
Lead sponsor
Essentia Water, LLC
Industry
Eligibility
25 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 30, 2026, 1:33 AM EDT
Withdrawn Phase 2 Interventional

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

NCT01271283
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Diagnostic Laboratory Biomarker Analysis, Lenalidomide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 30, 2026, 1:33 AM EDT
Completed Not applicable Interventional

The Influence of Cardiorespiratory Fitness on Firefighter Cardiovascular Health Under Exercise Conditions

NCT04514354
View directory record Official record
Conditions
Cardiovascular Diseases, Post-Exercise Hypotension
Interventions
GEST
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 30, 2026, 1:33 AM EDT
Completed No phase listed Observational

Transforming Research and Clinical Knowledge in Traumatic Brain Injury

NCT02119182
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
In-Person Outcome Assessment, Phone Outcome Assessment, 3T Magnetic Resonance Imaging (MRI), Blood Draw for Plasma, DNA, Serum, RNA
Behavioral · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 100 Years
Enrollment
2,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
23
States / cities
San Francisco, California • Denver, Colorado • Englewood, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 30, 2026, 1:33 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Eccentric Muscle Training, Stimulation, and Biomarkers in SCI

NCT05337982
View directory record Official record
Conditions
Spinal Cord Injuries, Healthy
Interventions
Downhill Eccentric Treadmill Training with Electrical Stimulation
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 85 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 30, 2026, 1:33 AM EDT